Loading
A phase 1/2 trial of Cemiplimab in melanoma and renal cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting.
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body is a phase 1/2 interventional study registered as NCT06413680 by Regeneron Pharmaceuticals, with 240 participants planned, started 2024-09-23 and due to reach its primary completion in 2030-02-03. Interventions recorded: REGN10597, Cemiplimab. Conditions listed: Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors. No results are recorded here; the registry entry is the source.
Shares Regeneron, Cemiplimab, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.